Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer-Reference-Cited by-同舟云学术

Docetaxel and cyclophosphamide as neoadjuvant chemotherapy in HER2-negative primary breast cancer

Published:2016-01-11 Issue:1 Volume:24 Page:63-68
ISSN:1340-6868
Container-title:Breast Cancer
language:en
Short-container-title:Breast Cancer

Author:

Nakatsukasa Katsuhiko,Koyama Hiroshi,Oouchi Yoshimi,Imanishi Seiichi,Mizuta Naruhiko,Sakaguchi Kouichi,Fujita Yoshifumi,Fujiwara Ikuya,Kotani Tatsuya,Matsuda Takayuki,Fukuda Kenichirou,Morita Midori,Kawakami Sadao,Kadotani Yayoi,Konishi Eiichi,Yanagisawa Akio,Taguchi Tetsuya

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Radiology Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12282-016-0666-7.pdf

Reference17 articles.

1. Wolmark N, Wnag J, Mamounas E, Bryant J, Fisher B. Prospective chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. J Natl Cancer Inst Monogr. 2001;30:96–102.

2. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol. 2003;21:4165–74.

3. Heys SD, Hutcheon AW, Sarkar TK, Ogston KN, Miller ID, Payne S, et al. Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 2002;3(Suppl 2):S69–74.

4. Henderson IC, Berry DA, Demetri GD, Cirrincione CT, Goldstein LJ, Martino S, et al. Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol. 2003;21:976–83.

5. Jones S, Holmes FA, O’Shaughnessy J, Blum JL, Vukelja SJ, McIntyre KJ, et al. Docetaxel with cyclophosphamide is associated with an overall survival benefit compared with doxorubicin and cyclophosphamide: 7-year follow-up of US Oncology Research Trial 9735. J Clin Oncol. 2009;27:1177–83.

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug repurposing: a retrospective revolution in breast cancer medicine;Discover Medicine;2024-07-12

2. Pathological Changes Following Neoadjuvant Endocrine Therapy (NAET): A Multicentre Study of 391 Breast Cancers;International Journal of Molecular Sciences;2024-07-05

3. Drug Repurposing and Molecular Insights in the Fight Against Breast Cancer;Biomedical and Pharmacology Journal;2024-06-25

4. Inflammation of actinic keratoses after the use of docetaxel plus cyclophosphamide;Current Problems in Cancer: Case Reports;2024-06

5. Exploratory drug discovery in breast cancer patients: A multimodal deep learning approach to identify novel drug candidates targeting RTK signaling;Computers in Biology and Medicine;2024-05